BioCentury
ARTICLE | Company News

Angle sales and marketing update

March 11, 2013 7:00 AM UTC

Angle launched its Parsortix cancer cell separation device for research use to a limited number of users worldwide. The company plans to seek FDA approval of the device and CE Mark approval for use in cancer treatment decisions, early detection of cancer and for monitoring of cancer patients during treatment and post-treatment. Parsortix plans to launch the device in Europe for clinical use by year end and hopes for a decision from FDA next year. The microscale cell separation device separates cells on the basis of size and/or surface interactions. ...